Deep Learning PET/CT-Based Radiomics Integrates Clinical Data: Application to Distinguish between Active Pneumonia and Lung Cancer

2022 ◽  
Author(s):  
Xiaolei Zhang ◽  
M. Iqbal Saripan ◽  
Shiqi Xu ◽  
Lijun Lu ◽  
Dongyang Du ◽  
...  
2021 ◽  
Author(s):  
Kareem A. Wahid ◽  
Renjie He ◽  
Cem Dede ◽  
Abdallah Sherif Radwan Mohamed ◽  
Moamen Abobakr Abdelaal ◽  
...  

PET/CT images provide a rich data source for clinical prediction models in head and neck squamous cell carcinoma (HNSCC). Deep learning models often use images in an end-to-end fashion with clinical data or no additional input for predictions. However, in the context of HNSCC, the tumor region of interest may be an informative prior in the generation of improved prediction performance. In this study, we utilize a deep learning framework based on a DenseNet architecture to combine PET images, CT images, primary tumor segmentation masks, and clinical data as separate channels to predict progression-free survival (PFS) in days for HNSCC patients. Through internal validation (10-fold cross-validation) based on a large set of training data provided by the 2021 HECKTOR Challenge, we achieve a mean C-index of 0.855 +- 0.060 and 0.650 +- 0.074 when observed events are and are not included in the C-index calculation, respectively. Ensemble approaches applied to cross-validation folds yield C-index values up to 0.698 in the independent test set (external validation). Importantly, the value of the added segmentation mask is underscored in both internal and external validation by an improvement of the C-index when compared to models that do not utilize the segmentation mask. These promising results highlight the utility of including segmentation masks as additional input channels in deep learning pipelines for clinical outcome prediction in HNSCC.


2019 ◽  
Author(s):  
Yu-Heng Lai ◽  
Wei-Ning Chen ◽  
Te-Cheng Hsu ◽  
Che Lin ◽  
Yu Tsao ◽  
...  

AbstractNon-small cell lung cancer (NSCLC) is one of the most common lung cancers worldwide. Accurate prognostic stratification of NSCLC can become an important clinical reference when designing therapeutic strategies for cancer patients. With this clinical application in mind, we developed a deep neural network (DNN) combining heterogeneous data sources of gene expression and clinical data to accurately predict the prognosis of NSCLC patients. Based on microarray data from a cohort set (614 patients), seven well-known NSCLC markers were used to group patients into marker- and marker+ subgroups. Using a systems biology approach, prognosis relevance values (PRV) were then calculated to select eight additional novel prognostic gene markers. Gene markers along with clinical data were then used to develop an integrative DNN via bimodal learning to predict the 5-year survival rate of NSCLC patients with tremendously high accuracy (AUC: 0.8163, accuracy: 75.44%), which is superior to all other existing methods based on AUC. Using the capability of deep learning, we believe that our predicted cancer prognosis can be a promising index helping oncologists and physicians develop personalized therapy and build the foundation of precision medicine in the future.


Sign in / Sign up

Export Citation Format

Share Document